In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Taft Leonard, David Gomez-Almaguer, Maria R. Baer, Carlo Gambacorti-Passerini, James K. McCloskey, Yosuke Minami, Cristina Papayannidis, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Lin Yang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Jose-Maria Ribera-Santasusana
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Hospital Universitari i Politècnic La Fe, Oregon Health & Science University, Universidad Autónoma de Nuevo León, Hospital Universitario Dr José Eleuterio Gonzalez, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Milano-Bicocca, Hackensack University Medical Center, National Cancer Center Hospital East, Istituto di Ematologia di Bologna, Centre Hospitalier de Versailles, University of Alabama at Birmingham, Roswell Park Comprehensive Cancer Center, Josep Carreras Leukaemia Research Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399519932